Navigation Links
Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
Date:7/9/2008

trials in solid tumor indications, including a Phase III clinical trial in combination with gemcitabine in locally advanced and metastatic pancreatic cancer. Lorus has reported that the overall survival data in this Phase III study did not reach statistical significance, although exploratory analysis yielded promising results in specific patient populations including in patients with ECOG performance status of 0 or 1.

In April 2008, Lorus' subsidiary GeneSense Technologies entered into an exclusive multinational license agreement for Virulizin(R) with Zor Pharmaceuticals LLC to further develop and commercialize Virulizin(R) for advanced pancreatic cancer and other therapy areas in North and South America, Europe, and Israel.

Virulizin(R) study leads to new drug candidate IL-17E

The article entitled "Virulizin(R) induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors" was published online in the journal Cancer Immunology Immunotherapy and is available through PubMed (http://www.ncbi.nlm.nih.gov/PubMed/).

The study showed that Virulizin(R) treatment stimulates the immune system to produce the cytokine IL-17E, which in turn triggers an anticancer effect through activation and tumor recruitment of eosinophils. This novel aspect of the anticancer mechanism of action for Virulizin(R) adds to previous studies showing that Virulizin(R) activates other cells of the immune system, including macrophages and Natural Killer (NK) cells.

A key finding of this report was that IL-17E itself had significant anticancer activity when used in mouse models of human cancers. Preliminary studies have revealed that IL-17E has potent activity against several human tumor types, including colon cancer, melanoma, and pancreatic cancer, with low toxicity. Lorus has patent applications pending in major markets, including Canada, Europe and the United St
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
(Date:7/24/2014)... Yan, Distinguished Professor of Engineering at the University ... to solve problems in energy engineering, environmental sustainability ... on zeolites, porous rock with a well-defined, crystalline ... is so precisely decided that zeolites can separate ... of an angstrom (one-tenth of a nanometer), making ...
(Date:7/24/2014)... July 24, 2014 SRI International has been ... National Institute of Allergy and Infectious Diseases (NIAID), part ... development of potential therapies for HIV infection and AIDS. ... HIV and AIDS and the complications and opportunistic infections ... preventing sexual transmission of HIV. According ...
(Date:7/24/2014)... July 24, 2014 WIRB-Copernicus Group ® ... and ethical review services for clinical research, announced ... a division of Richmond, VA ... biosafety and biosecurity consulting firm in ... WCG,s biosafety division – WCG Biosafety™ – will ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4University of Delaware researcher describes new approach for creating organic zeolites 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... Sept. 14 Helix BioPharma Corp. (TSX, FSE: "HBP" / ... list its shares of common stock on the NYSE Amex ... stock will begin trading on the NYSE Amex on September ... delist from the OTCQX once trading begins on the NYSE ...
... 14 The launch of IntriMed Technologies and ... in Oxnard, Calif. were announced today by IntriPlex ... manufacture of ultra-precise components for the data storage ... heritage of engineering innovation, IntriMed ( www.intrimed.com ) ...
... HARBIN, China, Sept. 14 /PRNewswire-Asia-FirstCall/ -- ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
Cached Biology Technology:Helix BioPharma Approved for NYSE Amex Listing 2Helix BioPharma Approved for NYSE Amex Listing 3IntriMed Technologies Launched to Address Challenges Faced by Medical Device Manufacturers 2IntriMed Technologies Launched to Address Challenges Faced by Medical Device Manufacturers 3Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 2Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 3Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 4Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 5Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 6Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 7Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 8
(Date:7/24/2014)... RIVERSIDE, Calif. -- To reduce fire hazard in the ... of mechanically cutting woody shrubs and suppressed trees (ladder ... then burned during periods of low fire danger in ... burning and minimize hazardous air pollutants, managers often cover ... polyethylene plastic, commonly referred to as agricultural plastic, in ...
(Date:7/24/2014)... study funded by the New Jersey Recovery Fund and ... of Planning and Public Policy at Rutgers University has ... skeptical about the likelihood of community-based rebuilding solutions. Of ... indicated they were "pessimistic" or "very pessimistic" that the ... be rebuilt better than they were before the storm; ...
(Date:7/24/2014)... which life arose have been maintained in our cells today ... Research published today in the Journal of Biological Chemistry ... also in animals still perform ancient reactions thought to have ... billion years ago. , The primordial soup theory suggests that ... of the combination of metals, gases from the atmosphere and ...
Breaking Biology News(10 mins):Study gives new perspective on agricultural plastic, debris burning, and air quality 2Rutgers study explores attitudes, preferences toward post-Sandy rebuilding 2
... It just got easier to pinpoint biological hot spots in ... a pinpoint. Microscopic algae are called phytoplankton and range from ... being 1/100th the size of a human hair. But as ... of Vancouver Island, British Columbia, are big players when it ...
... MD FASEB MARC (Minority Access to Research Careers) ... American Society for Bone & Mineral Research (ASBMR) 2010 ... 2010. These awards are meant to promote the ... the mainstream of the basic science community and to ...
... October 6, 2010 - A first-of-its-kind study that tracked the ... tagged in the Hudson River discovered that these fish move ... south as Georgia and as far north as Nova Scotia, ... will need to address long-range oceanic threats to the species ...
Cached Biology News:UW-built device reveals invisible world teeming with microscopic algae 2Study provides data that can inform Atlantic sturgeon recovery efforts 2Study provides data that can inform Atlantic sturgeon recovery efforts 3
...
... receptors constitute the principal excitatory ... classes of glutamate receptors exist: ... Ionotropic glutamate receptors are oligomeric ... NMDA1-3, KAI-2) which comprise ligand-gated ...
Identify and characterize Phosphoinositide (PI(4,5)P2) binding...
Recommended fro Western blotting application...
Biology Products: